Typhoid conjugate vaccine (Novartis)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameTyphoid conjugate vaccine (Novartis)

Drug Alias Name伤寒结合疫苗 - 诺华Vi-CRM197 glycoconjugated vaccine,NVGH Vi-CRM197 vaccine,Vi-CRM(197)NVGH glycoconjugate vaccine against S. typhiSalmonella monovalent typhi vaccineVi-CRM197 vaccine +[7]

ClassificationVaccines > Development/production technology > Conjugated vaccineVaccines > Biological material > Bacterial vaccineVaccines > Application > Prophylactic vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsTyphoid Fever

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumPakistanPhilippines +[4]

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNovartis Pharma Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNovartis Pharma Ag

Active IndicationsN/A

Inactive IndicationsTyphoid Fever

Other Information

ATC CodeN/A